Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01940900) enrolled 626 people in total — 311 in one group and 315 in the other. Participants were split into two groups: one group received a treatment called E10030 combined with ranibizumab (an eye injection), and the other received a sham procedure (a dummy, inactive procedure) combined with ranibizumab. The trial was primarily measuring changes in vision over 12 months, using a standard eye-chart scoring system called ETDRS letters, where a higher score means better vision. The reported data shows that after 12 months, both groups had higher vision scores compared to where they started. The group receiving E10030 plus ranibizumab had an average increase of about 9.91 letters on the eye chart, while the group receiving the sham procedure plus ranibizumab had an average increase of about 10.36 letters. No secondary outcome measure data was included in the structured results provided. It is also worth noting that not everyone completed the trial — 29 people in the first group and 31 in the second group did not finish. The reported data shows only these two numbers for the primary outcome, and no further breakdown or additional outcome results were available in the submitted data. If any other measurements were taken during the trial, they were not reported in the data provided here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 30957581) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Macular Degeneration Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 50 years of age or older (any gender)
- You have been diagnosed with an abnormal growth of blood vessels under the central part of your retina (the back of your eye), caused by age-related macular degeneration (AMD)
- A specific type of eye scan (called an SD-OCT) has shown a certain type of material building up beneath your retina (confirm with trial site)
Who may not be able to join:
- You have previously received any treatment for AMD in the eye being studied, unless it was only vitamin or mineral supplements taken by mouth
- You have ever had any injection of medication into the eye being studied, for any reason
- You have had surgery inside your eye, or a certain type of laser treatment, within the last 3 months — or you have ever had laser treatment to the central area of your retina for any reason
- You have scarring or tissue loss directly in the central area of your retina
- You have diabetes
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Mean Change in Visual Acuity From Baseline to 12 Months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.